Q-omics provides the consensus-scored TMEM169 profile across patient tissues and cancer cell-line models. TMEM169 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TMEM169 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, TMEM169 RNA expression shows 19,439 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight STAD, KICH, and KIRP as cancer lineages where TMEM169 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM169 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM169 survival associations across molecular data types. TMEM169 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM169 RNA expression–survival associations across cancer types. High TMEM169 expression shows unfavorable associations in STAD, UCEC and ACC, but favorable associations in KIRC, HNSC and LGG. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for TMEM169 RNA expression.
This table summarizes TMEM169 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM169. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM169 shows lower tumor expression in KICH, COAD and KIRC and higher tumor expression in HNSC, LIHC and CHOL. The KICH box plot shows higher TMEM169 RNA expression in normal versus tumor tissue (log2 FC = −2.621, t-test p < 0.001).
This table shows molecular features associated with TMEM169 in patient tissues and cancer cell lines. In patient samples, TMEM169 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM169 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
